| 2021 marked the lowest number of new drug shortages in 10 years; however, existing drug shortages are not resolving, and the number of ongoing and active shortages is increasing.
Regulatory, supply and manufacturing quality issues continue to contribute to the shortage problem. Vulnerable populations, like pediatrics, tend to be the most impacted as generic injectables for oncology, immunology, and other therapeutic areas have been on recent short supply lists. Now the question is, how do we fix this?
Learn about hidden costs, mitigating risks, and solutions to end drug shortages. |
